Bicara Therapeutics (BCAX) EBT (2023 - 2026)

Bicara Therapeutics has reported EBT for 4 years, with the latest figure at -$56.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 52.71% year-over-year to -$56.2 million; the trailing twelve-month figure through Mar 2026 stood at -$157.1 million (down 70.64% YoY), and the FY2025 full-year result was -$137.7 million, down 103.12% from the prior year.
• EBT for Q1 2026 stood at -$56.2 million, down from -$37.3 million in the prior quarter.
• The five-year high for EBT was -$12.4 million in Q4 2023, with the low at -$56.2 million in Q1 2026.
• Historically, EBT has averaged -$27.0 million across 4 years, with a median of -$22.8 million in 2023.
• Annual changes were most pronounced in 2024 — EBT increased 23.48% — and 2025, when it slumped 194.03%.
• Bicara Therapeutics' EBT stood at -$12.4 million in 2023, then plunged by 67.04% to -$20.8 million in 2024, then tumbled by 79.74% to -$37.3 million in 2025, then tumbled by 50.43% to -$56.2 million in 2026.
• The last three EBT figures came in at -$56.2 million (Q1 2026), -$37.3 million (Q4 2025), and -$36.3 million (Q3 2025), per Business Quant data.